Symbols / CURX Stock $0.44 +1.40% Curanex Pharmaceuticals Inc
CURX (Stock) Chart
About
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.
Stock Fundamentals
Scroll to Statements| Market Cap | 12.56M | Enterprise Value | 19.13M | Income | -435.03K | Sales | — | Book/sh | 0.01 | Cash/sh | 0.00 |
| Dividend Yield | — | Payout | 0.00% | Employees | — | IPO | — | P/E | — | Forward P/E | — |
| PEG | — | P/S | — | P/B | 34.08 | P/C | — | EV/EBITDA | — | EV/Sales | — |
| Quick Ratio | 1.43 | Current Ratio | 9.37 | Debt/Eq | 155.99 | LT Debt/Eq | — | EPS (ttm) | -0.02 | EPS next Y | — |
| EPS Growth | — | Revenue Growth | — | Earnings | — | ROA | -30.03% | ROE | -85.25% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 28.34M | Shs Float | 8.91M | Short Float | 0.67% |
| Short Ratio | 0.03 | Short Interest | — | 52W High | 9.18 | 52W Low | 0.26 | Beta | — | Avg Volume | 4.40M |
| Volume | 123.91K | Target Price | — | Recom | None | Prev Close | $0.44 | Price | $0.44 | Change | 1.40% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.44
Latest analyst target
3. DCF / Fair value
$-0.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.44
Low
—
High
—
Mean
—
- Curanex (CURX) Stock: What Is Driving the Price (Momentum Building) 2026-04-20 - Real Time Stock Idea Network - UBND thành phố Hải Phòng Mon, 20 Apr 2026 14
- CURX (Curanex) CEO highlights upcoming specialty drug launches as core growth driver for coming fiscal year. - P/B Ratio - Cổng thông tin điện tử tỉnh Tây Ninh hu, 23 Apr 2026 00
- symbol__ Stock Quote Price and Forecast - CNN ue, 19 Aug 2025 15
- Five critically ill patient accounts inform Curanex's cachexia focus - Stock Titan Wed, 08 Apr 2026 07
- CURX (Curanex) CEO highlights upcoming specialty drug launches as core growth driver for coming fiscal year. - Neutral Rating - Xã Thanh Hà hu, 23 Apr 2026 10
- CURX Stock Price and Chart — NASDAQ:CURX - TradingView ue, 26 Aug 2025 18
- Should I Sell Curanex (CURX) Stock Now | Price at $0.52, Up 6.06% - Swing Trade - Cổng thông tin điện tử tỉnh Lào Cai Mon, 06 Apr 2026 07
- EXCLUSIVE: Penny Stock Curanex Expands Cachexia Focus Backed By Patient Recovery Narratives - Benzinga Wed, 08 Apr 2026 07
- Ulcerative colitis drug candidate stays on track for late-2026 filing - Stock Titan Mon, 30 Mar 2026 07
- CURX Ownership | CURANEX PHARMACEUTICALS INC (NASDAQ:CURX) - ChartMill Fri, 19 Sep 2025 06
- CURX Should I Buy - Intellectia AI ue, 03 Mar 2026 09
- No U.S.-approved treatment exists for cancer cachexia. Curanex adds it - Stock Titan hu, 02 Apr 2026 07
- What's Behind Curanex Pharmaceuticals (CURX) 56% Surge After Hours - Benzinga hu, 26 Feb 2026 08
- CURANEX PHARMACEUTICALS INC (CURX) Fundamental Analysis & Valuation - ChartMill Fri, 19 Sep 2025 02
- One cancer patient kept working 2+ years in Curanex Phyto-N case - Stock Titan Mon, 06 Apr 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.03
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.03
|
| Cost Of Revenue |
|
—
|
—
|
0.00
-100.00%
|
0.02
|
| Reconciled Cost Of Revenue |
|
—
|
—
|
0.00
-100.00%
|
0.02
|
| Gross Profit |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Operating Expense |
|
4.24
+1359.81%
|
0.29
+1404.75%
|
0.02
-21.75%
|
0.02
|
| Research And Development |
|
2.99
|
0.00
|
—
|
—
|
| Selling General And Administration |
|
1.25
+331.56%
|
0.29
+1404.75%
|
0.02
-21.75%
|
0.02
|
| General And Administrative Expense |
|
1.25
+331.56%
|
0.29
+1404.75%
|
0.02
-21.75%
|
0.02
|
| Other Gand A |
|
1.25
+331.56%
|
0.29
+1404.75%
|
0.02
-21.75%
|
0.02
|
| Total Expenses |
|
4.24
+1359.81%
|
0.29
+1404.75%
|
0.02
-58.26%
|
0.05
|
| Operating Income |
|
-4.24
-1359.81%
|
-0.29
-1404.75%
|
-0.02
+4.62%
|
-0.02
|
| Total Operating Income As Reported |
|
-4.24
-1061.19%
|
-0.37
-1791.71%
|
-0.02
+4.62%
|
-0.02
|
| EBITDA |
|
-4.14
-1044.43%
|
-0.36
-1967.76%
|
-0.02
-1990.05%
|
0.00
|
| Normalized EBITDA |
|
-4.14
-1342.38%
|
-0.29
-1540.62%
|
-0.02
-1990.05%
|
0.00
|
| Reconciled Depreciation |
|
0.08
|
0.00
-100.00%
|
0.00
-91.42%
|
0.02
|
| EBIT |
|
-4.22
-1066.39%
|
-0.36
-1773.28%
|
-0.02
+4.62%
|
-0.02
|
| Total Unusual Items |
|
0.00
+100.00%
|
-0.07
|
0.00
|
—
|
| Total Unusual Items Excluding Goodwill |
|
0.00
+100.00%
|
-0.07
|
0.00
|
—
|
| Special Income Charges |
|
0.00
+100.00%
|
-0.07
|
0.00
|
—
|
| Impairment Of Capital Assets |
|
0.00
-100.00%
|
0.07
|
0.00
|
—
|
| Net Income |
|
-4.23
-1068.75%
|
-0.36
-1783.04%
|
-0.02
+5.12%
|
-0.02
|
| Pretax Income |
|
-4.23
-1068.75%
|
-0.36
-1783.04%
|
-0.02
+5.12%
|
-0.02
|
| Net Non Operating Interest Income Expense |
|
-0.01
|
0.00
|
—
|
—
|
| Interest Expense Non Operating |
|
0.01
|
0.00
|
—
|
—
|
| Net Interest Income |
|
-0.01
|
0.00
|
—
|
—
|
| Interest Expense |
|
0.01
|
0.00
|
—
|
—
|
| Other Income Expense |
|
0.02
+131.65%
|
-0.07
-71220.00%
|
0.00
|
—
|
| Other Non Operating Income Expenses |
|
0.02
+532.93%
|
0.00
+3456.00%
|
0.00
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-4.23
-1068.75%
|
-0.36
-1783.04%
|
-0.02
+5.12%
|
-0.02
|
| Net Income From Continuing Operation Net Minority Interest |
|
-4.23
-1068.75%
|
-0.36
-1783.04%
|
-0.02
+5.12%
|
-0.02
|
| Net Income From Continuing And Discontinued Operation |
|
-4.23
-1068.75%
|
-0.36
-1783.04%
|
-0.02
+5.12%
|
-0.02
|
| Net Income Continuous Operations |
|
-4.23
-1068.75%
|
-0.36
-1783.04%
|
-0.02
+5.12%
|
-0.02
|
| Normalized Income |
|
-4.23
-1373.03%
|
-0.29
-1394.06%
|
-0.02
+5.12%
|
-0.02
|
| Net Income Common Stockholders |
|
-4.23
-1068.75%
|
-0.36
-1783.04%
|
-0.02
+5.12%
|
-0.02
|
| Diluted EPS |
|
—
|
-0.01
-1782.51%
|
-0.00
+96.54%
|
-0.02
|
| Basic EPS |
|
—
|
-0.01
-1782.51%
|
-0.00
+96.54%
|
-0.02
|
| Basic Average Shares |
|
—
|
27.75
-33.93%
|
42.00
+0.00%
|
42.00
|
| Diluted Average Shares |
|
—
|
42.00
+0.00%
|
42.00
+0.00%
|
42.00
|
| Diluted NI Availto Com Stockholders |
|
-4.23
-1068.75%
|
-0.36
-1783.04%
|
-0.02
+5.12%
|
-0.02
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
11.58
+2135.83%
|
0.52
+596.47%
|
0.07
+626.80%
|
0.01
|
| Current Assets |
|
11.23
+2067.74%
|
0.52
+596.47%
|
0.07
+626.80%
|
0.01
|
| Cash Cash Equivalents And Short Term Investments |
|
4.97
+3240.12%
|
0.15
+100.21%
|
0.07
+2960.33%
|
0.00
|
| Cash And Cash Equivalents |
|
4.97
+3240.12%
|
0.15
+100.21%
|
0.07
+2960.33%
|
0.00
|
| Cash Financial |
|
4.97
+3240.12%
|
0.15
+100.21%
|
0.07
+2960.33%
|
0.00
|
| Receivables |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Inventory |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Prepaid Assets |
|
6.25
+530381.26%
|
0.00
|
0.00
|
—
|
| Current Deferred Assets |
|
0.00
-100.00%
|
0.37
|
0.00
|
—
|
| Other Current Assets |
|
—
|
0.37
|
—
|
0.00
|
| Total Non Current Assets |
|
0.35
|
0.00
|
0.00
|
0.00
|
| Net PPE |
|
0.35
|
0.00
|
—
|
—
|
| Gross PPE |
|
0.35
|
0.00
|
—
|
—
|
| Other Properties |
|
0.35
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
0.36
+2377.12%
|
0.01
+2.09%
|
0.01
|
0.00
|
| Current Liabilities |
|
0.14
+840.17%
|
0.01
+2.09%
|
0.01
|
0.00
|
| Payables And Accrued Expenses |
|
0.01
-1.61%
|
0.01
+2.09%
|
0.01
|
0.00
|
| Payables |
|
0.00
-51.22%
|
0.01
+737.50%
|
0.00
|
—
|
| Accounts Payable |
|
0.00
-51.48%
|
0.01
|
0.00
|
—
|
| Current Accrued Expenses |
|
0.01
+24.50%
|
0.01
-30.17%
|
0.01
|
0.00
|
| Total Tax Payable |
|
0.00
+0.00%
|
0.00
-95.83%
|
0.00
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
0.12
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.12
|
0.00
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.22
|
0.00
|
0.00
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
0.22
|
0.00
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
0.22
|
0.00
|
—
|
—
|
| Stockholders Equity |
|
11.22
+2128.84%
|
0.50
+737.68%
|
0.06
+487.28%
|
0.01
|
| Common Stock Equity |
|
11.22
+2129.26%
|
0.50
+737.51%
|
0.06
+487.28%
|
0.01
|
| Capital Stock |
|
0.00
+17.36%
|
0.00
+4066.67%
|
0.00
-40.00%
|
0.00
|
| Common Stock |
|
0.00
+18.08%
|
0.00
+3900.00%
|
0.00
-40.00%
|
0.00
|
| Preferred Stock |
|
0.00
+0.00%
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
28.34
+2.13%
|
27.75
+0.00%
|
27.75
+0.00%
|
27.75
|
| Ordinary Shares Number |
|
28.34
+2.13%
|
27.75
+0.00%
|
27.75
+0.00%
|
27.75
|
| Additional Paid In Capital |
|
16.06
+1639.80%
|
0.92
+663.24%
|
0.12
+133.19%
|
0.05
|
| Retained Earnings |
|
-4.85
-678.79%
|
-0.62
-138.54%
|
-0.26
-7.94%
|
-0.24
|
| Total Equity Gross Minority Interest |
|
11.22
+2128.84%
|
0.50
+737.68%
|
0.06
+487.28%
|
0.01
|
| Total Capitalization |
|
11.22
+2128.84%
|
0.50
+737.68%
|
0.06
+487.28%
|
0.01
|
| Working Capital |
|
11.09
+2103.29%
|
0.50
+737.68%
|
0.06
+487.28%
|
0.01
|
| Invested Capital |
|
11.22
+2129.26%
|
0.50
+737.51%
|
0.06
+487.28%
|
0.01
|
| Total Debt |
|
0.35
|
0.00
|
—
|
—
|
| Capital Lease Obligations |
|
0.35
|
0.00
|
—
|
—
|
| Net Tangible Assets |
|
11.22
+2128.84%
|
0.50
+737.68%
|
0.06
+487.28%
|
0.01
|
| Tangible Book Value |
|
11.22
+2129.26%
|
0.50
+737.51%
|
0.06
+487.28%
|
0.01
|
| Duefrom Related Parties Current |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Other Equity Interest |
|
—
|
0.20
+0.00%
|
0.20
+0.00%
|
0.20
|
| Preferred Stock Equity |
|
0.00
+0.00%
|
0.00
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-10.48
-1787.14%
|
-0.56
-462879.17%
|
-0.00
-103.60%
|
0.00
|
| Cash Flow From Continuing Operating Activities |
|
-10.48
-1787.14%
|
-0.56
-462879.17%
|
-0.00
-103.60%
|
0.00
|
| Net Income From Continuing Operations |
|
-4.23
-1068.75%
|
-0.36
-1783.04%
|
-0.02
+5.12%
|
-0.02
|
| Depreciation Amortization Depletion |
|
0.08
|
0.00
-100.00%
|
0.00
-91.42%
|
0.02
|
| Depreciation |
|
0.08
|
0.00
-100.00%
|
0.00
-91.42%
|
0.02
|
| Depreciation And Amortization |
|
0.08
|
0.00
-100.00%
|
0.00
-91.42%
|
0.02
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
0.07
|
—
|
—
|
| Change In Working Capital |
|
-6.34
-2258.65%
|
-0.27
-1656.77%
|
0.02
+616.01%
|
0.00
|
| Change In Inventory |
|
—
|
0.00
-100.00%
|
0.00
-86.15%
|
0.02
|
| Change In Prepaid Assets |
|
-6.25
-530289.99%
|
-0.00
|
0.00
|
—
|
| Change In Payables And Accrued Expense |
|
-0.00
-178.26%
|
0.00
-97.91%
|
0.01
|
0.00
|
| Change In Accrued Expense |
|
0.00
+149.78%
|
-0.00
-132.93%
|
0.01
|
0.00
|
| Change In Payable |
|
-0.00
-151.48%
|
0.01
|
—
|
—
|
| Change In Account Payable |
|
-0.00
-151.48%
|
0.01
|
0.00
|
—
|
| Change In Other Current Assets |
|
0.00
+100.00%
|
-0.27
|
0.00
|
—
|
| Change In Other Current Liabilities |
|
-0.09
|
0.00
|
0.00
+100.00%
|
-0.02
|
| Financing Cash Flow |
|
15.31
+2329.57%
|
0.63
+774.46%
|
0.07
+2501.87%
|
-0.00
|
| Cash Flow From Continuing Financing Activities |
|
15.31
+2329.57%
|
0.63
+774.46%
|
0.07
+2501.87%
|
-0.00
|
| Net Common Stock Issuance |
|
15.66
+2384.95%
|
0.63
+812.30%
|
0.07
|
0.00
|
| Net Other Financing Charges |
|
-0.35
|
—
|
0.00
+200.00%
|
-0.00
|
| Changes In Cash |
|
4.82
+6373.32%
|
0.07
+3.60%
|
0.07
+21309.52%
|
0.00
|
| Beginning Cash Position |
|
0.15
+100.21%
|
0.07
+2960.33%
|
0.00
+16.05%
|
0.00
|
| End Cash Position |
|
4.97
+3240.12%
|
0.15
+100.21%
|
0.07
+2960.33%
|
0.00
|
| Free Cash Flow |
|
-10.48
-1787.14%
|
-0.56
-462879.17%
|
-0.00
-103.60%
|
0.00
|
| Common Stock Issuance |
|
15.66
+2384.95%
|
0.63
+812.30%
|
0.07
|
0.00
|
| Issuance Of Capital Stock |
|
15.66
+2384.56%
|
0.63
+812.45%
|
0.07
|
0.00
|
| Net Preferred Stock Issuance |
|
0.00
-100.00%
|
0.00
|
0.00
|
—
|
| Preferred Stock Issuance |
|
0.00
-100.00%
|
0.00
|
0.00
|
—
|
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|